Global Prader-Willi Syndrome Therapeutics Market 2018-2022 | Designations for Special Drugs Impacting Market Growth | Technavio
LONDON--(BUSINESS WIRE)--Jan 2, 2019--The global Prader-Willi Syndrome Therapeutics market 2018-2022 is expected to post a CAGR of close to 5% during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190102005308/en/
Technavio predicts the global Prader-Willi Syndrome Therapeutics market to post a CAGR of close to 5% by 2022. (Graphic: Business Wire)
A key factor driving the growth of the market is designations for special drugs. Prader-Willi Syndrome is a rare disorder and its prevalence rate is usually lower compared with other mainstream indications. Thus, drug manufacturers often hesitate to invest a large amount in drug discovery. To overcome such hurdles, regulatory bodies grant designations for special drugs which support the further development of therapeutics for the treatment of Prader-Willi syndrome. Thus, the increasing of designations for special drugs from regulatory bodies is expected to drive the growth of the Prader-Willi syndrome market.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the strong drug pipeline as one of the key emerging trends in the global Prader-Willi syndrome market:
Global Prader-Willi syndrome therapeutics market: Strong drug pipeline
The number of drug pipeline in the global Prader-Willi syndrome (PWS) therapeutics market is increasing at a good pace. The drug pipeline has many promising therapeutic agents, which are expected to boost the growth of the market during the forecast period. Also, the number of clinical trials is continuously increasing for the development of therapeutics for the treatment of Prader-Willi syndrome which is expected to drive the market growth.
“In April 2018, GeneScience Pharmaceuticals started a multi-center phase III study to evaluate the efficacy and safety of jintropin AQ in patients with PWS. Also, approximately 15 therapeutics for Prader-Willi syndrome are under different stages of development in the drug pipeline,” says a senior analyst at Technavio.
Global Prader-Willi syndrome therapeutics market: Segmentation analysis
This market research report segments the global Prader-Willi syndrome therapeutics market by product (recombinant growth hormones and others) and geographical regions (APAC, EMEA, and the Americas).
The Americas led the market in 2017 with a market share of close to 47%, followed by EMEA and APAC respectively. The dominance of the Americas can be attributed to the designations for special drugs and increasing strategic alliances.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005308/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 01/02/2019 08:28 AM/DISC: 01/02/2019 08:28 AM